Mar 01, 2023 / 02:30PM GMT
Daniel R. Grosslight - Citigroup Inc., Research Division - Research Analyst
All right. We shall begin again. So Daniel Grosslight, Healthcare Technology Analyst here at Citi, joined by Joe Selsavage, the CFO of 23andMe. Thank you all for joining us today. You know 23andMe is a bit of an (inaudible), if you don't mind me saying that, in that there's a lot of different types of companies in one. So I guess just see the sense of the room here. How many of you folks are focused more on biotech, life sciences. A couple health tech diagnostics. So it's a fair mix, which I think is -- brings a lot of opportunity but also perhaps one great home for you, which tends to be an issue, some of that.
Questions and Answers:
Daniel R. Grosslight - Citigroup Inc., Research Division - Research AnalystSo I guess if we just start off to begin with on the consumer side, you had a good quarter this past quarter in terms of kit demand. That's where people, I think most know you from reflects a little less discounting this quarter than perhaps in previous quarters. So can you